About ResQ Pharma
ResQ Pharma is a private company based in Glenview, Illinois. It has reported $2,390,000 raised in five offerings on Form D since March 2016.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Jul 27, 2024 | Dec 31, 2024 | $99,999of $100K target | 1 | $99,999 | EquityRule 506(b) | Form D ↗ |
| May 13, 2022 | Jun 16, 2022 | $205,501of $300K target | 6 | $34,250 | EquityRule 506(b) | Form D ↗ |
| Jun 22, 2020 | Sep 10, 2020 | $1,020,000of $2.0M target | 6 | $170K | EquityRule 506(b) | Form D ↗ |
| Aug 31, 2016 | Sep 16, 2016 | $739,500of $764K target | 13 | $56,885 | EquityRule 506(b) | Form D ↗ |
| Sep 17, 2015 | Mar 2, 2016 | $325,000fully sold | 8 | $40,625 | EquityRule 506(b) | Form D ↗ |
| Total, five offerings | $2,390,000 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on ResQ Pharma's Form D filed Dec 31, 2024.
Earlier filings also listed Todd Beck (executive officer, director and promoter, last listed Sep 2020), Steve Bylina (executive officer, director and promoter, last listed Sep 2020), Paul Hertz (executive officer, director and promoter, last listed Sep 2020), Francis Wisniewski (executive officer, director and promoter, last listed Sep 2020), Antoinette Gawin (executive officer, director and promoter, last listed Sep 2020), Paul Burton (chief executive officer and director, last listed Sep 2016), Israel Rubinstein (director, last listed Mar 2016) and David Bowman (executive officer, last listed Mar 2016).